Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial

Lancet Haematol. 2026 May;13(5):e315-e326. doi: 10.1016/S2352-3026(26)00043-8.ABSTRACTBACKGROUND: Second generation tyrosine kinase inhibitors (TKIs) have improved response rates in patients with chronic phase chronic myeloid leukaemia (CP-CML)....
close chatgpt icon
ChatGPT

Enter your request.

CME/CPD